Table 1.
Basic information about TSH suppression and CVD risk after thyroid cancer surgery.
| Study | Research design | Sample size(Treat/control) | Gender (M/F) | Age (y) | Follow-up duration (y) | ||
|---|---|---|---|---|---|---|---|
| Treat | control | Treat | control | ||||
| Suh et al, 2019 (8) | Cohort | 182419:182419 | 22822/153597 | 22822/153597 | 47 ± 11.3 | 47 ± 11.3 | 4.3 |
| JoseÍ Botella-Carretero et al, 2004 (9) | Cohort | 19:21 | Female | Female | 42.6 ± 14.1 | 42.7 ± 14.5 | 3.8 ± 4.5 |
| Toulis et al, 2019 (10) | Cohort | 3009: 11 303 | 722/2287 | 2713/8590 | 50.7 ± 16.1 | 50.4 ± 15.7 | NA |
| Biondi et al, 1993 (11) | Cohort | 20:20 | 2/8 | 3/17 | 36 ± 11 | 40 ± 9 | 1-9 |
| Shuvy et al, 2008 (12) | Case-control | 20:20 | NA | NA | 41.9 ± 12.3 | 41.7 ± 12.2 | NA |
| Ve´ ronique Taillard et al, 2011 (13) | Case-control | 24:20 | 9/34 | 4/19 | 54 ± 14 | 50 ± 11 | 3 ± 0.9 |
| Hong et al. et al, 2016 (14) | Case-control | 14:14 | Female | Female | 42.9 ± 7.2 | 42.9 ± 6.5 | 6.9 |
| Murialdo et al, 2005 (15) | Cohort | 11:31 | 1/10 | 3/28 | 56.7 ± 89.4 | 54.3 ± 15.6 | NA |
| Shargorodsky et al, 2006 (16) | Cohort | 26:26 | 23/3 | 22/4 | 52.8 | 52.6 | 6.7 |
| Klein Hesselink et al, 2015 (17) | Cohort | 518:1563 | 131/387 | 372/1164 | 48.6 ± 14.0 | 48.6 ± 13.4 | 8 |
| Nelli Pajamäki et al, 2018 (18) | Cohort | 901:4485 | 171/730 | 897/3588 | 48.8 ± 15.9 | 48.7 ± 15.8 | NA |
| Mittal et al, 2012 (19) | Case-control | 50:50 | 12/38 | 12/38 | 58.9 ± 11 | 57.6 ± 10 | NA |
| Mercuro et al, 2000 (20) | Case-control | 19:19 | 3/16 | 4/15 | 44.3 ± 11.8 | 41.1 ± 11.5 | 5.7 ± 3.5 |
| Hpftjizer et al, 2009 | Case-control | 14:24 | 2/12 | 4/20 | 51.6 ± 14.5 | 45.4 ± 8.5 | NA |
NA, No specific classification.